SKiN Health

52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial

BACKGROUND: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To describe efficacy and safety outcomes through Week 52. METHODS: In this multicentr...

Assessing Challenges and Barriers to Effective Wound Care in Rural Indigenous Communities

OBJECTIVE: To explore the lived experiences of patients with chronic wounds from a remote Indigenous community in Northern Manitoba, Canada, focusing on challenges in wound management, the impact on quality of life, barriers to wound care access, and the role of traditional heali...